Search Results - "Korman, Alan J."

The foundations of immune checkpoint blockade and the ipilimumab approval decennial by Korman, Alan J., Garrett-Thomson, Sarah C., Lonberg, Nils

“…Cancer immunity, and the potential for cancer immunotherapy, have been topics of scientific discussion and experimentation for over a hundred years. Several…”
Get full text

FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis by Dahan, Rony, Sega, Emanuela, Engelhardt, John, Selby, Mark, Korman, Alan J., Ravetch, Jeffrey V.

“…Immune checkpoint blockade of the programmed cell death protein 1 (PD-1) pathway by monoclonal antibodies (Abs) has shown promising clinical benefit in the…”
Get full text

Evolving synergistic combinations of targeted immunotherapies to combat cancer by Melero, Ignacio, Berman, David M., Aznar, M. Angela, Korman, Alan J., Gracia, José Luis Pérez, Haanen, John

“…Key Points Clinical trials have validated immuno-oncology as a new pillar of anticancer therapy. Combinations could involve two (or more) sequential or…”
Get full text

Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology by Selby, Mark J, Engelhardt, John J, Johnston, Robert J, Lu, Li-Sheng, Han, Minhua, Thudium, Kent, Yao, Dapeng, Quigley, Michael, Valle, Jose, Wang, Changyu, Chen, Bing, Cardarelli, Pina M, Blanset, Diann, Korman, Alan J

“…The monoclonal antibodies ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) have shown remarkable antitumor activity in an increasing number of cancers. When…”
Get full text

Blood–brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy by Galstyan, Anna, Markman, Janet L., Shatalova, Ekaterina S., Chiechi, Antonella, Korman, Alan J., Patil, Rameshwar, Klymyshyn, Dmytro, Tourtellotte, Warren G., Israel, Liron L., Braubach, Oliver, Ljubimov, Vladimir A., Mashouf, Leila A., Ramesh, Arshia, Grodzinski, Zachary B., Penichet, Manuel L., Black, Keith L., Holler, Eggehard, Sun, Tao, Ding, Hui, Ljubimov, Alexander V., Ljubimova, Julia Y.

“…Brain glioma treatment with checkpoint inhibitor antibodies to cytotoxic T-lymphocyte-associated antigen 4 (a-CTLA-4) and programmed cell death-1 (a-PD-1) was…”
Get full text

Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy by Marciscano, Ariel E, Ghasemzadeh, Ali, Nirschl, Thomas R, Theodros, Debebe, Kochel, Christina M, Francica, Brian J, Muroyama, Yuki, Anders, Robert A, Sharabi, Andrew B, Velarde, Esteban, Mao, Wendy, Chaudhary, Kunal R, Chaimowitz, Matthew G, Wong, John, Selby, Mark J, Thudium, Kent B, Korman, Alan J, Ulmert, David, Thorek, Daniel L J, DeWeese, Theodore L, Drake, Charles G

“…In the proper context, radiotherapy can promote antitumor immunity. It is unknown if elective nodal irradiation (ENI), a strategy that irradiates…”
Get full text

Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab by Ramagopal, Udupi A., Liu, Weifeng, Garrett-Thomson, Sarah C., Bonanno, Jeffrey B., Yan, Qingrong, Srinivasan, Mohan, Wong, Susan C., Bell, Alasdair, Mankikar, Shilpa, Rangan, Vangipuram S., Deshpande, Shrikant, Korman, Alan J., Almo, Steven C.

“…Rational modulation of the immune response with biologics represents one of the most promising and active areas for the realization of new therapeutic…”
Get full text

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates by BRAHMER, Julie R, DRAKE, Charles G, GILSON, Marta M, CHANGYU WANG, SELBY, Mark, TAUBE, Janis M, ANDERS, Robert, LIEPING CHEN, KORMAN, Alan J, PARDOLL, Drew M, LOWY, Israel, TOPALIAN, Suzanne L, WOLLNER, Ira, POWDERLY, John D, PICUS, Joel, SHARFMAN, William H, STANKEVICH, Elizabeth, PONS, Alice, SALAY, Theresa M, MCMILLER, Tracee L

“…Programmed death-1 (PD-1), an inhibitory receptor expressed on activated T cells, may suppress antitumor immunity. This phase I study sought to determine the…”
Get full text

TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection by Chew, Glen M, Fujita, Tsuyoshi, Webb, Gabriela M, Burwitz, Benjamin J, Wu, Helen L, Reed, Jason S, Hammond, Katherine B, Clayton, Kiera L, Ishii, Naoto, Abdel-Mohsen, Mohamed, Liegler, Teri, Mitchell, Brooks I, Hecht, Frederick M, Ostrowski, Mario, Shikuma, Cecilia M, Hansen, Scott G, Maurer, Mark, Korman, Alan J, Deeks, Steven G, Sacha, Jonah B, Ndhlovu, Lishomwa C

“…HIV infection induces phenotypic and functional changes to CD8+ T cells defined by the coordinated upregulation of a series of negative checkpoint receptors…”
Get full text

Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape by Noguchi, Takuro, Ward, Jeffrey P, Gubin, Matthew M, Arthur, Cora D, Lee, Sang Hun, Hundal, Jasreet, Selby, Mark J, Graziano, Robert F, Mardis, Elaine R, Korman, Alan J, Schreiber, Robert D

“…Antibody blockade of programmed death-1 (PD-1) or its ligand, PD-L1, has led to unprecedented therapeutic responses in certain tumor-bearing individuals, but…”
Get more information

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma by Wolchok, Jedd D., Hodi, F. Stephen, Weber, Jeffrey S., Allison, James P., Urba, Walter J., Robert, Caroline, O'Day, Steven J., Hoos, Axel, Humphrey, Rachel, Berman, David M., Lonberg, Nils, Korman, Alan J.

“…The immunotherapeutic agent ipilimumab has helped address a significant unmet need in the treatment of advanced melanoma. Ipilimumab is a fully human…”
Get full text

BMS-936564/MDX-1338: A Fully Human Anti-CXCR4 Antibody Induces Apoptosis In Vitro and Shows Antitumor Activity In Vivo in Hematologic Malignancies by KUHNE, Michelle R, MULVEY, Tanya, COHEN, Lewis J, KORMAN, Alan J, CARDARELLI, Pina M, BELANGER, Blake, CHEN, Sharline, PAN, Chin, COLIN CHONG, FEI CAO, NIEKRO, Wafa, KEMPE, Tom, HENNING, Karla A

“…CXCR4 has been identified as a prognostic marker for acute myeloid leukemia (AML) and other malignancies. We describe the development and characterization of a…”
Get full text

FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis by Dahan, Rony, Sega, Emanuela, Engelhardt, John, Selby, Mark, Korman, Alan J., Ravetch, Jeffrey V.

Get full text

A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection by Gardiner, David, Lalezari, Jay, Lawitz, Eric, DiMicco, Michael, Ghalib, Rheem, Reddy, K Rajender, Chang, Kyong-Mi, Sulkowski, Mark, Marro, Steven O', Anderson, Jeffrey, He, Bing, Kansra, Vikram, McPhee, Fiona, Wind-Rotolo, Megan, Grasela, Dennis, Selby, Mark, Korman, Alan J, Lowy, Israel

“…Expression of the programmed death 1 (PD-1) receptor and its ligands are implicated in the T cell exhaustion phenotype which contributes to the persistence of…”
Get full text

Blockade ofthe negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis by Chang, Katherine C, Burnham, Carey-Ann, Compton, Stephanie M, Rasche, David P, Mazuski, RichardJ, SMcDonough, Jacquelyn, Unsinger, Jacqueline, Korman, Alan J, Green, Jonathan M, Hotchkiss, Richard S

“…Abstract Introduction Fungal sepsis is an increasingly common problem in intensive care unit patients.Mortality from fungal sepsis remains high despite…”
Get full text

Anticancer immunotherapy by CTLA-4 blockade： obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25 by Hannani, Dalil, Vétizou, Marie, Enot, David, Rusakiewicz, Sylvie, Chaput, Nathalie, Klatzmann, David, Desbois, Melanie, Jacquelot, Nicolas, Vimond, Nadège, Chouaib, Salem, Mateus, Christine, Allison, James P, Ribas, Antoni, Wolchok, Jedd D, Yuan, Jianda, Wong, Philip, Postow, Michael, Mackiewicz, Andrzej, Mackiewicz, Jacek, Schadendorff, Dirk, Jaeger, Dirk, Korman, Alan J, Bahjat, Keith, Maio, Michele, Calabro, Luana, Teng, Michele WL, Smyth, Mark J, Eggermont, Alexander, Robert, Caroline, Kroemer, Guido, Zitvogel, Laurence

“…The cytotoxic T lymphocyte antigen-4 （CTLA-4）-blocking antibody ipilimumab induces immune-mediated longterm control of metastatic melanoma in a fraction of…”
Get full text

Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates by Brahmer, Julie R, Drake, Charles G, Wollner, Ira, Powderly, John D, Picus, Joel, Sharfman, William H, Stankevich, Elizabeth, Pons, Alice, Salay, Theresa M, McMiller, Tracee L, Gilson, Marta M, Wang, Changyu, Selby, Mark, Taube, Janis M, Anders, Robert, Chen, Lieping, Korman, Alan J, Pardoll, Drew M, Lowy, Israel, Topalian, Suzanne L

“…Programmed death-1 (PD-1), an inhibitory receptor expressed on activated T cells, may suppress antitumor immunity. This phase I study sought to determine the…”
Get full text

An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients by Colston, Elizabeth, Grasela, Dennis, Gardiner, David, Bucy, R Pat, Vakkalagadda, Blisse, Korman, Alan J, Lowy, Israel

“…Expression of cytotoxic T-lymphocyte antigen 4 (CTLA-4), a negative regulator of T-cell function, is increased in chronic HIV-1 infection. It was hypothesized…”
Get full text

Cutting edge: accelerated autoimmune diabetes in the absence of LAG-3 by Bettini, Maria, Szymczak-Workman, Andrea L, Forbes, Karen, Castellaw, Ashley H, Selby, Mark, Pan, Xiaoyu, Drake, Charles G, Korman, Alan J, Vignali, Dario A A

“…Lymphocyte activation gene-3 (LAG-3; CD223) is a CD4 homolog that is required for maximal regulatory T cell function and for the control of CD4(+) and CD8(+) T…”
Get full text

TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer by Maas, Ralph Ja, Hoogstad-van Evert, Janneke S, Van der Meer, Jolien Mr, Mekers, Vera, Rezaeifard, Somayeh, Korman, Alan J, de Jonge, Paul Kjd, Cany, Jeannette, Woestenenk, Rob, Schaap, Nicolaas Pm, Massuger, Leon F, Jansen, Joop H, Hobo, Willemijn, Dolstra, Harry

“…Advanced ovarian cancer (OC) patients have a poor 5-year survival of only 28%, emphasizing the medical need for improved therapies. Adjuvant immunotherapy…”
Get full text